{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:35:17Z","timestamp":1757453717630,"version":"3.40.5"},"reference-count":85,"publisher":"Microbiology Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,3]]},"abstract":"<jats:p>Human respiratory syncytial virus (hRSV) is a major cause of respiratory illness in young children and can cause severe infections in the elderly or in immunocompromised adults. To date, there is no vaccine to prevent hRSV infections, and disease management is limited to preventive care by palivizumab in infants and supportive care for adults. Intervention with small-molecule antivirals specific for hRSV represents a good alternative, but no such compounds are currently approved. The investigation of existing drugs for new therapeutic purposes (drug repositioning) can be a faster approach to address this issue. In this study, we show that chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A (long strain) and synergistically increase the anti-replicative effect of ribavirin<jats:italic>in cellulo<\/jats:italic>. Moreover, chloroquine, but not pyrimethamine, inhibits hRSV replication in the mouse model. Our results show that chloroquine can potentially be an interesting compound for treatment of hRSV infection in monotherapy or in combination with other antivirals.<\/jats:p>","DOI":"10.1099\/jgv.0.001627","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T14:16:40Z","timestamp":1628000200000},"source":"Crossref","is-referenced-by-count":4,"title":["Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A"],"prefix":"10.1099","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-3454","authenticated-orcid":false,"given":"Fryad","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, High Quality Laboratory, Anwar Sheikha Medical City, Sulaymaniyah, Iraq"},{"name":"Department of Biology, College of Science, University of Sulaimani, Kurdistan Region, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Libre","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellis\u00e9e Ligue Contre le Cancer, Universit\u00e9 de Lyon, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Oleinikov","sequence":"additional","affiliation":[{"name":"Charles E. Schmidt College of Medicine, Department of Biomedical Science, Florida Atlantic University, 777 Glades Rd, Boca Raton, FL, 33431, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Tcherniuk","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Virologie et Immunologie Mol\u00e9culaires, INRA, Universit\u00e9 Paris SaclayJouy-en-Josas, France"},{"name":"Department of Biological Sciences, Youth Academy of Sciences, Kiev, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02571-12"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200522070-00004"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.13.3.371-384.2000"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit471"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-3-203"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021"},{"year":"2019","key":"R7","article-title":"Respiratory syncytial virus (RSV"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12313"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330430042027"},{"key":"R10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1542\/peds.72.5.613","article-title":"Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants","volume":"72","author":"Taber","year":"1983","journal-title":"Pediatrics"},{"key":"R11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/archpedi.1996.02170340056011","article-title":"Ribavirin for respiratory syncytial virus lower respiratory tract infection","volume":"150","author":"Randolph","year":"1996","journal-title":"Asystematic overview Arch Pediatr Adolesc Med"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702228"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702078"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-263400"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu623"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401184"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy227"},{"key":"R18","article-title":"Safety and Efficacy of Oral RV521 in a Human Respiratory Syncytial Virus (RSV) Phase 2a Challenge Study","volume":"197","author":"De Vicenzo","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12503"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1016\/j"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413275"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky415"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.04.006"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04119-14"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu828"},{"key":"R26","first-page":"1476","article-title":"Results of a phase 2b multicenter trial of ALN-RSV01 in respiratory syncytial virus (RSV)- infected lung transplant patients","volume":"40","author":"Simon","year":"2012","journal-title":"Eur Respir J"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001916"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1470727"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2011.09.020"},{"key":"R30","first-page":"11","article-title":"Emerging viral diseases","volume":"9","author":"Pekosz","year":"2008","journal-title":"Md Med"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-08"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.017"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.09.034"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2012.165"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.016"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.08.018"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104762"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-021-11094-4"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.79830-0"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6104"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.1.251-259.1999"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006453"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006920"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.02.040"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"R48","first-page":"1","volume-title":"Examination of Clinical Trial Costs and Barriers for Drug Development","author":"Sertkaya","year":"2014"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.24612"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-020-00216-7"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.02.011"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.03.006"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26141"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/s1386-6532(00)00139-6"},{"key":"R58","doi-asserted-by":"publisher","DOI":"10.1007\/bf01320970"},{"key":"R59","first-page":"149","article-title":"Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report","volume":"15","author":"Kouroumalis","year":"1986","journal-title":"Ann Acad Med Singap"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0132-9"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-3-39"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-64-5-1149"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22019"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12154"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.3390\/v8120322"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.1007\/BF01313817"},{"key":"R67","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00164-09"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.017269-0"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.03.005"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000309"},{"key":"R71","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(84)90356-8"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101738"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03011-14"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(03)00806-5"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0936"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00758"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr338"},{"volume-title":"Pyrimethamine Inhibits STAT3 Transcriptional Activity Via Dihydrofolate Reductase. Proceedings of the American Association for Cancer Research Annual Meeting 2019","year":"2019","author":"Heppler","key":"R80"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2017.06.004"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1159\/000220858"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200112000-00015"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90131-7"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406927102"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.001627?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T09:53:21Z","timestamp":1672998801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"URL":"https:\/\/doi.org\/10.1099\/jgv.0.001627","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"type":"print","value":"0022-1317"},{"type":"electronic","value":"1465-2099"}],"subject":[],"published":{"date-parts":[[2021,8,3]]}}}